These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 16689133)

  • 1. [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient].
    Kastelan D; Korsić M
    Reumatizam; 2005; 52(2):67-70. PubMed ID: 16689133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M
    Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
    Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
    J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Raloxifene (Celvista, Evista)].
    Body JJ; Sternon J
    Rev Med Brux; 2000 Feb; 21(1):35-41. PubMed ID: 10748686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
    Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
    J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective estrogen receptor modulators and postmenopausal health.
    Roe EB; Chiu KM; Arnaud CD
    Adv Intern Med; 2000; 45():259-78. PubMed ID: 10635051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
    Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
    Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
    Maeda T; Ke HZ; Simmons H; Thompson D
    Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
    Ohta H
    Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
    Sambrook P
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety assessment of raloxifene over eight years in a clinical trial setting.
    Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL
    Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Selective estrogen receptor modulators (SERMs)].
    Matsumoto T
    Clin Calcium; 2006 Sep; 16(9):1520-25. PubMed ID: 16951478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [SERMs for treatment of osteoporosis: state-of-the-art and perspectives].
    Legrand E; Hoppé E; Chappard D; Audran M
    Gynecol Obstet Fertil; 2006 May; 34(5):423-8. PubMed ID: 16697240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
    Palacios S
    Curr Med Res Opin; 2010 Jul; 26(7):1553-63. PubMed ID: 20429824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing and treating osteoporosis: strategies at the millennium.
    Sherman S
    Ann N Y Acad Sci; 2001 Dec; 949():188-97. PubMed ID: 11795353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.
    Silverman SL; Delmas PD; Kulkarni PM; Stock JL; Wong M; Plouffe L
    J Am Geriatr Soc; 2004 Sep; 52(9):1543-8. PubMed ID: 15341559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Raloxifene in postmenopausal women].
    Trémollières F; Ribot C
    Gynecol Obstet Fertil; 2006 Feb; 34(2):147-53. PubMed ID: 16483822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.